George N Dalekos
Overview
Explore the profile of George N Dalekos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
226
Citations
4200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kyriazopoulou E, Akinosoglou K, Florou E, Kouriannidi E, Bogosian A, Tsachouridou O, et al.
Int J Antimicrob Agents
. 2024 Dec;
65(1):107405.
PMID: 39647797
Background: Anakinra was approved by the European Medicines Agency and received Emergency Use Authorization by the United States Food and Drug Administration for patients with COVID-19 pneumonia at risk for...
2.
Papaefthymiou A, Sarrou S, Pateras K, Vachliotis I, Agrotis G, Sgantzou I, et al.
Pharmaceuticals (Basel)
. 2024 Nov;
17(11).
PMID: 39598344
Background: Biologic agents used in patients with inflammatory bowel diseases (IBD) may influence the pathophysiology of coexistent metabolic-dysfunction associated steatotic liver disease (MASLD). This study primarily aimed to evaluate the...
3.
Dalekos G, Papatheodoridis G, Koskinas J, Goulis I, Rigopoulou E, Tiniakos D
Ann Gastroenterol
. 2024 Nov;
37(6):623-654.
PMID: 39568707
Autoimmune hepatitis (AIH) is a rare liver disease, of unknown origin, characterized by considerable heterogeneity. AIH can affect both sexes, of all ages, ethnicities and races. The revised Clinical Practice...
4.
Brandes-Leibovitz R, Riza A, Yankovitz G, Pirvu A, Dorobantu S, Dragos A, et al.
Cell Rep Med
. 2024 Nov;
5(11):101829.
PMID: 39566468
Patients with sepsis differ in their clinical presentations and immune dysregulation in response to infection, but the fundamental processes that determine this heterogeneity remain elusive. Here, we aim to understand...
5.
Olivas I, Arvaniti P, Gabeta S, Torres S, Del Barrio M, Diaz-Gonzalez A, et al.
JHEP Rep
. 2024 Nov;
6(11):101213.
PMID: 39524208
Background & Aims: Liver stiffness measurement (LSM) has been shown to adequately predict outcomes in patients with liver disease. However, the value of LSM as a predictor of disease progression...
6.
Kranidioti E, Ricano-Ponce I, Antonakos N, Kyriazopoulou E, Kotsaki A, Tsangaris I, et al.
Crit Care Med
. 2024 Oct;
52(11):e536-e544.
PMID: 39418210
Objective: To investigate the metabolomic profiles associated with different immune activation states in sepsis patients. Design: Subgroup analysis of the PROVIDE (a Personalized Randomized trial of Validation and restoration of...
7.
Roberts S, Choi W, Worobetz L, Vincent C, Flemming J, Cheung A, et al.
JHEP Rep
. 2024 Oct;
6(10):101168.
PMID: 39380718
Background & Aims: Biochemical response to ursodeoxycholic acid (UDCA) therapy is associated with good prognosis in people living with primary biliary cholangitis (PBC). Biochemical response is typically assessed early in...
8.
Karakike E, Metallidis S, Poulakou G, Kosmidou M, Gatselis N, Petrakis V, et al.
Crit Care Explor
. 2024 Sep;
6(9):e1153.
PMID: 39263383
Objectives: It is suggested that sepsis may be classified into four clinical phenotypes, using an algorithm employing 29 admission parameters. We applied a simplified phenotyping algorithm among patients with bacterial...
9.
Stern L, Schmidt C, Kocheise L, Joerg V, Casar C, Walter A, et al.
Ann Hepatol
. 2024 Aug;
29(6):101534.
PMID: 39147132
Introduction And Objectives: Autoimmune liver diseases (AILD) are rare causes hepatocellular carcinoma (HCC), and data on the efficacy and tolerability of anti-tumor therapies are scarce. This pan-European study aimed to...
10.
Gomez-Huelgas R, Dalekos G, Dicker D, Montano N
Eur J Intern Med
. 2024 Aug;
128:26-29.
PMID: 39097415
Healthcare systems face multiple challenges arising from demographic factors (population aging) and epidemiological factors (rise of chronic diseases and patients with multimorbidity) as well as threats to their financial sustainability...